Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
121-140 of 653 trials

Atopic Dermatitis: PF-07275315 and PF-07264660

We are investigating two new treatments for adults with moderate to severe atopic dermatitis. The study aims to see if they are more effective than a placebo in reducing eczema symptoms.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsCost ReimbursementPartially RemoteAllergologyDermatology

COPD Treatment: Understanding ICS Response

We are studying how different eosinophil levels affect the response to inhaled corticosteroids in COPD patients. This research may help personalize treatment strategies for better management of the disease.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyPulmonology

Coronary Disease: Tirzepatide Study

We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.

Overweight and Obesity1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Diffuse Large B-Cell Lymphoma: Epcoritamab with R-CHOP

We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.

Diffuse Large B-Cell Lymphoma1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

Multiple Sclerosis Relapse1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsNeurology

Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

Advanced Melanoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Multiple Sclerosis: Annual vs. Semi-Annual Ocrelizumab Infusions

We are comparing the effects of annual and semi-annual infusions of ocrelizumab in patients with active multiple sclerosis. The goal is to see which schedule better prevents disease activity over two years.

Multiple Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurology

Memory Disorders: Evaluating Tau PET Imaging

We are studying whether tau PET can improve diagnosis for patients with memory problems. This trial compares its effectiveness to more common and affordable diagnostic tools.

Mild Cognitive Impairment and Dementia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurology

Giant Cell Arteritis: Stopping Tocilizumab

We are comparing immediate versus gradual stopping of tocilizumab in patients with giant cell arteritis. The goal is to see which method helps prevent relapses and improves quality of life.

Giant Cell Arteritis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesRheumatology

Ceftazidime-Avibactam for Critically Ill Patients

We are studying the best dosing of ceftazidime-avibactam for critically ill patients on continuous renal replacement therapy. This research aims to improve treatment effectiveness and safety.

Ceftazidime-avibactam Therapy1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology

Pulmonary Arterial Hypertension: Treprostinil Palmitil Inhalation Powder

We are studying the long-term safety and effects of an inhalation powder for people with pulmonary arterial hypertension. This research aims to see if it improves exercise capacity and overall health.

Pulmonary Arterial Hypertension1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Immune Thrombocytopenia: Avatrombopag vs. Rituximab

We are comparing the effectiveness of Avatrombopag and Rituximab in adults with ITP who did not respond to corticosteroids. The study aims to see which treatment better improves health-related quality of life and reduces fatigue.

Immune Thrombocytopenia1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal Medicine

Chronic Migraine in Adolescents: Rimegepant Study

We are investigating whether rimegepant can help prevent migraines in adolescents aged 12 to under 18 with chronic migraine. The study will also assess its safety and how it affects the use of other migraine treatments.

Chronic Migraine1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Spinal Muscular Atrophy: Risdiplam Study for Infants

We are investigating how the medication risdiplam works and its safety in infants with spinal muscular atrophy. This study aims to provide important insights into its use for this condition.

Spinal Muscular Atrophy1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Richter's Syndrome: M-CHOP with Mosunetuzumab

We are studying a new treatment combining mosunetuzumab with CHOP for patients with Richter's Syndrome who have not had therapy before. The aim is to evaluate its effectiveness and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Lupus Treatment: BIIB059 Study

We are testing a new medication, BIIB059, for people with active subacute or chronic cutaneous lupus who haven't responded to standard treatments. The study aims to see if it can reduce skin disease activity and improve overall safety.

Skin Lupus1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Ulcerative Colitis: Lutikizumab Treatment Study

We are assessing the safety and effectiveness of lutikizumab in adults with active ulcerative colitis. This study compares it to an existing treatment to see if it offers better results.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Diabetic Retinopathy: COLIRIOBCN070660 Eye Drops

We are studying a new eye drop treatment for people with moderately severe to severe diabetic retinopathy. The goal is to see if it can reduce eye damage and improve vision.

Diabetic Retinopathy1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesEndocrinologyOphthalmology

Severe Hemophilia A: Efanesoctocog Alfa Study

We are comparing a new treatment, efanesoctocog alfa, with other existing therapies for severe hemophilia A. This study aims to understand how well it works in managing the condition.

Haemophilia A1-2 yearsSafety phase (I)Hematology

Nonsegmental Vitiligo: Ritlecitinib Study

We are investigating the safety and effectiveness of ritlecitinib in adults and adolescents with nonsegmental vitiligo. This study looks at how well the medication works over time for those who have already been treated.

Non-Segmental Vitiligo1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology